Verastem Oncology Announces Key Management Appointments
February 20 2019 - 7:00AM
Business Wire
Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the
Company), a biopharmaceutical company focused on developing and
commercializing medicines seeking to improve the survival and
quality of life of cancer patients, today announced several key
appointments to its management team. The recent additions to the
Verastem Oncology senior team include Amy C. Cavers as Senior Vice
President, Strategic Engagement and Alignment, Robert Morgan, M.S.,
J.D., as Senior Vice President, Development Operations, and Erin S.
Cox as Senior Director of Investor Relations and Corporate
Communications.
“Verastem Oncology continues to grow our operations across the
U.S. in crucial functional areas, such as commercial management,
clinical development, medical affairs, regulatory, quality
assurance and investor relations and communications,” said Robert
Forrester, President and Chief Executive Officer of Verastem
Oncology. “We are delighted to welcome Amy, Bob and Erin to our
team to support us in our mission of bringing new cancer therapies
to patients and families battling these devastating diseases. We
will greatly benefit from Amy’s successful product launch expertise
and deep knowledge of the b-cell malignancies space. Bob is also an
important addition that will help guide the organization and
advancement of our pipeline of therapies to late-stage development.
Erin’s extensive IR and communications experience in the
biotechnology industry will be critical as we continue to increase
our presence within the financial community.” Ms. Cox has a proven
track-record of managing complex investor relations and corporate
communication programs at publicly-traded biopharmaceutical
companies. She most recently served as an Investor Relations
Consultant at Antisense Therapeutics, Ltd., an Australian-based
biotechnology company focused on rare disease, and previously led
the investor relations and communications functions at Sarepta
Therapeutics and PhaseRX, Inc. Earlier in her career, she held
director-level market intelligence and investor relations roles at
several investor relations agencies as well as at The NASDAQ OMX
Group. She started her career as an investment banking analyst at
Montgomery Securities. Ms. Cox holds a B.A. in communications and
journalism from the University of Washington.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial
biopharmaceutical company committed to the development and
commercialization of medicines to improve the lives of patients
diagnosed with cancer. We are driven by the strength, tenacity and
courage of those battling cancer – single-minded in our resolve to
deliver new therapies that not only keep cancer at bay, but improve
the lives of patients diagnosed with cancer. Because for us, it’s
personal.
Our first FDA approved product is now available for the
treatment of patients with certain types of indolent non-Hodgkin’s
lymphoma (iNHL). Our pipeline comprises product candidates that
seek to treat cancer by modulating the local tumor
microenvironment. For more information, please visit
www.verastem.com.
Forward looking statements notice
This press release includes forward-looking statements about
Verastem Oncology’s strategy, future plans and prospects, including
statements regarding the development and activity of Verastem
Oncology’s lead product duvelisib, and Verastem Oncology’s PI3K and
FAK programs generally, its intent to commercialize duvelisib, the
potential commercial success of duvelisib, the anticipated adoption
of duvelisib by patients and physicians, the structure of its
planned and pending clinical trials and the timeline and
indications for clinical development, regulatory submissions and
commercialization activities. The words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could,"
"should," "continue," and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statement. Applicable risks and
uncertainties include, among other things, uncertainties regarding
the commercial success of duvelisib in the United States;
uncertainties regarding physician and patient adoption of
duvelisib, including those related to the safety and efficacy of
duvelisib; the uncertainties inherent in research and development
of duvelisib, such as negative or unexpected results of clinical
trials; whether and when any applications for duvelisib may be
filed with regulatory authorities in any other jurisdictions;
whether and when regulatory authorities in any other jurisdictions
may approve any such other applications that may be filed for
duvelisib, which will depend on the assessment by such regulatory
authorities of the benefit-risk profile suggested by the totality
of the efficacy and safety information submitted and, if approved,
whether duvelisib will be commercially successful in such
jurisdictions; Verastem Oncology’s ability to obtain, maintain and
enforce patent and other intellectual property protection for
duvelisib and its other product candidates; the scope, timing, and
outcome of any legal proceedings; decisions by regulatory
authorities regarding labeling and other matters that could affect
the availability or commercial potential of duvelisib; that
regulatory authorities in the U.S. or other jurisdictions, if
approved, could withdraw approval; whether preclinical testing of
Verastem Oncology’s product candidates and preliminary or interim
data from clinical trials will be predictive of the results or
success of ongoing or later clinical trials; that the timing, scope
and rate of reimbursement for Verastem Oncology’s product
candidates is uncertain; the risk that third party payors
(including government agencies) will not reimburse for duvelisib;
that there may be competitive developments affecting its product
candidates; that data may not be available when expected; that
enrollment of clinical trials may take longer than expected; that
duvelisib or Verastem Oncology’s other product candidates will
cause unexpected safety events, experience manufacturing or supply
interruptions or failures, or result in unmanageable safety
profiles as compared to their levels of efficacy; that duvelisib
will be ineffective at treating patients with lymphoid
malignancies; that Verastem Oncology will be unable to successfully
initiate or complete the clinical development and eventual
commercialization of its product candidates; that the development
and commercialization of Verastem Oncology’s product candidates
will take longer or cost more than planned; that Verastem Oncology
may not have sufficient cash to fund its contemplated operations;
that Verastem Oncology or Infinity Pharmaceuticals, Inc. will fail
to fully perform under the duvelisib license agreement; that
Verastem Oncology may be unable to make additional draws under its
debt facility or obtain adequate financing in the future through
product licensing, co-promotional arrangements, public or private
equity, debt financing or otherwise; that Verastem Oncology will
not pursue or submit regulatory filings for its product candidates,
including for duvelisib in patients with CLL/SLL or FL in other
jurisdictions; and that Verastem Oncology’s product candidates will
not receive regulatory approval, become commercially successful
products, or result in new treatment options being offered to
patients.
Other risks and uncertainties include those identified under the
heading "Risk Factors" in the Company’s Quarterly Report on Form
10-Q for the quarterly period ended September 30, 2018 as filed
with the Securities and Exchange Commission (SEC) on November 7,
2018, its Annual Report on Form 10-K for the year ended December
31, 2017 as filed with the SEC on March 13, 2018 and in any
subsequent filings with the SEC. The forward-looking statements
contained in this press release reflect Verastem Oncology’s views
as of the date hereof, and the Company does not assume and
specifically disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190220005093/en/
Verastem Oncology:Erin CoxSenior Director, Investor Relations
and Corporate Communications+1
781-469-1553ecox@verastem.comInvestors:Joseph RayneArgot Partners+1
617-340-6075joseph@argotpartners.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024